Agios Pharmaceuticals, Inc. (AGIO) Wednesday said its Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary goal of hemoglobin response.
42.3% of patients treated with mitapivat achieved a hemoglobin response, compared to 1.6% of patients who were given placebo.
Hemoglobin response was defined as an increase of more than or equal to 1 g/dL in average hemoglobin concentrations from Week 12 through Week 24 compared with baseline.
Agios is also advancing Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia and expects to announce topline data in mid-2024.
The company plans to file for regulatory approval of mitapivat as a treatment for thalassemia by the end of 2024.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.